Detalhe da pesquisa
1.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299578
2.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Ann Hematol
; 102(6): 1501-1511, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37088816
3.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Lancet Oncol
; 23(3): 416-427, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35151415
4.
Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Br J Haematol
; 196(4): 954-962, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34726261
5.
Bone metabolism parameters and their relation to cytogenetics in multiple myeloma.
Eur J Haematol
; 109(1): 75-82, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35306691
6.
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Neoplasma
; 69(6): 1474-1479, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36591805
7.
Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.
Int J Mol Sci
; 23(23)2022 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36499093
8.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
BMC Cancer
; 21(1): 73, 2021 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451293
9.
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Eur J Haematol
; 107(4): 466-474, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272773
10.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Future Oncol
; 17(19): 2499-2512, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769076
11.
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Br J Haematol
; 190(2): 189-197, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32163180
12.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Lancet
; 394(10214): 2096-2107, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31735560
13.
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Ann Hematol
; 99(5): 1049-1061, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236735
14.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med
; 372(2): 142-52, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482145
15.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Blood
; 128(9): 1174-80, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27439911
16.
Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.
Klin Onkol
; 31(3): 213-229, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30441975
17.
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
Eur J Haematol
; 99(2): 186-189, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28470777
18.
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Eur J Haematol
; 99(1): 80-90, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28384387
19.
Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.
J Transl Med
; 14(1): 150, 2016 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27234807
20.
Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Eur J Haematol
; 96(2): 119-27, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25816709